Organization (Industry)
RESMED INC.
ClinicalTrials.gov lists RESMED INC. as lead sponsor of 105 trials.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 6 registered with a 2026 start date. The dashed outline is the pace from the 6 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 4.4 trial starts a year over the five years to September, under the 5 a year the method needs. 2 trials are registered to start in 2027 or later.
Logo Smoothape~commonswiki, via Wikimedia Commons, CC0. Shown to identify the organization; it may be a registered trademark.
This page covers RESMED INC.: 105 lead-sponsored trials and 8 legal-entity registrations.
Disease areas (46)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Sleep Apnea Syndromes | 94 |
| Sleep Apnea, Obstructive | 69 |
| Pulmonary Disease, Chronic Obstructive | 20 |
| Heart Failure | 19 |
| Respiratory Insufficiency | 11 |
Showing 5 of 46 disease areas.
Trials by start year as sponsor or collaborator (23)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 2 trials are registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 6 |
| 2025 | 4 |
| 2024 | 3 |
| 2023 | 4 |
| 2022 | 5 |
| 2021 | 2 |
| 2020 | 6 |
| 2019 | 7 |
| 2018 | 10 |
| 2017 | 7 |
Showing 10 of 23 years.
Prediction, not a registry value: median of 23 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; registered median of 10 months across 86 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 54% hit target (n=26) | 59% on time (n=29) |
Journals published in (103)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Sleep | 21 |
| Chest | 17 |
| American journal of respiratory and critical care medicine | 15 |
| Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine | 13 |
| The New England journal of medicine | 11 |
Showing 5 of 103 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 2,074 | 594 | 2025-12-30 |
SEC-reported annual financials (12)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2026 | 5,653,443,000 | 1,523,293,000 | 378,285,000 |
| 2025 | 5,146,327,000 | 1,400,723,000 | 331,284,000 |
| 2024 | 4,685,297,000 | 1,020,951,000 | 307,525,000 |
| 2023 | 4,222,993,000 | 897,556,000 | 287,642,000 |
| 2022 | 3,578,127,000 | 779,437,000 | 253,575,000 |
| 2021 | 3,196,825,000 | 474,505,000 | 225,284,000 |
| 2020 | 2,957,013,000 | 621,674,000 | 201,946,000 |
| 2019 | 2,606,572,000 | 404,592,000 | 180,651,000 |
| 2018 | 2,340,196,000 | 315,588,000 | 155,149,000 |
| 2017 | 2,066,700,000 | 342,284,000 | 144,467,000 |
Showing 10 of 12 fiscal years.
Financing and grant events (11)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-06-30 | Other financing | not disclosed | Sec extracted |
| 2026-01-29 | Other financing | not disclosed | Sec extracted |
| 2024-01-24 | Other financing | not disclosed | Sec extracted |
| 2023-08-03 | Other financing | not disclosed | Sec extracted |
| 2023-04-27 | Other financing | not disclosed | Sec extracted |
Showing 5 of 11 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 3 |
FDA recalls (2)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| Quattro Air FFM MED AMER, Product Code: 62702, full face mask for use with active-exhaust-valve ventilators | Class II | 2016-07-12 |
| Astral 100, 150 Model: 27001, 27003 In the US, Astral devices are primarily used as non-invasive homecare devices, for example, the largest population of patients on the Astral device is COPD patients primarily using the device at night with some daytime use for recovery breathing. While it is possible that there may be scenarios where critically dependent patients may encounter this scenario, the likelihood of this leading to harm is negligible because critically dependent patients will have a form of backup ventilation as standard of care. | Class II | 2016-01-13 |
Manufacturing and distribution sites (2)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| ResMed Corp | Lithia Spgs, US | FDA | |
| RESMED CORP | San Diego, US | FDA |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (89)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Royal Brompton & Harefield NHS Foundation Trust | Co sponsors trial with | 4 |
| University Hospital, Grenoble | Co sponsors trial with | 3 |
| Sociedad Española de Neumología y Cirugía Torácica | Co sponsors trial with | 3 |
| Air Liquide (France) | Co sponsors trial with | 3 |
| CRI-The Clinical Research Institute GmbH | Co sponsors trial with | 3 |
Showing 5 of 89 relationships.
Latest dated events (2,256)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2028-08-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-01-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-07-28 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-07 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 2,256 events.
Biomarker capability evidence (212)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ACE | Trial sponsor | Named in trial inclusion criteria |
| CLSTN2 | Trial sponsor | Named in trial inclusion criteria |
| EGR3 | Trial sponsor | Named in trial inclusion criteria |
| ERCC8 | Trial collaborator | Named in trial inclusion criteria |
| F10 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 212 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, approved assets, fda warning letters, fda untitled letters, fda import refusals, clia clinical laboratory certificates, and biomarkers this organization publishes on.